Home・Lista de Ações・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Fechado

SetorSaúde

89.57 4.96

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

81.34

Máximo

85.94

Indicadores-chave
By Trading Economics
Rendimento	-161M -133M
Vendas	-190M 74M
P/E Médio do Setor	47.744 64.641
EPS	-0.93
Margem de lucro	-180.007
Funcionários	711
EBITDA	-165M -107M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+20.68% upside

Dividendos
By Acuity
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.4B 12B
Abertura anterior	84.61
Fecho anterior	89.57

Sentimento de Notícias

By Acuity

50%

151 / 340 Ranking em Healthcare

Arrowhead Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in Monday's session. Broader market positivity follows President Trump's military announcement, impacting crude oil prices.

31 de jul. de 2026, 19:16 UTC

Correlated Moves

Arrowhead Pharmaceuticals shares are lower, reflecting broader pressures in the biotechnology sector amid rising inflation concerns linked to increased crude oil prices.

30 de jul. de 2026, 23:06 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, with no specific news identified to explain the movement amid broader market volatility.

29 de jul. de 2026, 20:09 UTC

News

Social Media

RBC Capital raised Arrowhead Pharmaceuticals' price target to $100 from $87, contributing to positive sentiment and modest gains since Tuesday's close.

28 de jul. de 2026, 23:31 UTC

Arrowhead Pharmaceuticals shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and significant declines in other indices.

27 de jul. de 2026, 19:02 UTC

News

Social Media

Event

Arrowhead Pharmaceuticals completed enrollment in its Phase 3 YOSEMITE trial for zodasiran, with H.C. Wainwright and Morgan Stanley raising price targets to $115 and $120, respectively.

24 de jul. de 2026, 19:12 UTC

Social Media

Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $120, but shares are trading lower amid increased market volume during Friday's session.

23 de jul. de 2026, 10:16 UTC

News

Event

Arrowhead Pharmaceuticals shares rise in pre-market trading, building on Wednesday's gains after positive drug trial results and a price target increase to $115 from $90.

22 de jul. de 2026, 22:06 UTC

Event

Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies, boosting shares higher in after-market trading.

21 de jul. de 2026, 20:12 UTC

Arrowhead Pharmaceuticals Inc. shares declined in after-market trading, remaining below the 20-day moving average and near the lower end of the one-month range.

20 de jul. de 2026, 20:21 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours, declining from a high to a low amid unusual trading activity and no specific news identified.

Comparação entre Pares

Variação de preço

Arrowhead Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

20.68% parte superior

Previsão para 12 meses

Média 103.8 USD 20.68%

Máximo 126 USD

Mínimo 46 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Arrowhead Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Arrowhead Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

151 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.